FDA Approves First-in-Class RAS Inhibitor for Metastatic Pancreatic Cancer
The US Food and Drug Administration approved daraxonrasib (brand name Rasonque, made by Revolution Medicines, Inc.) on August 26, 2026, for the treatment of metastatic pancreatic adenocarcinoma — the most common form of pancreatic cancer. It is the first drug in an entirely new class of targeted therapy to reach approval for this disease. The FDA accepted the drug's application for review on July 22, 2026, and delivered its decision roughly five weeks later, well ahead of the standard review window. That speed was driven by a Breakthrough Therapy designation granted in 2025, which allows the agency to fast-track drugs for serious conditions with few good treatment options. (FDA press release, FDA approved-drugs notice)
To understand why this matters, it helps to know what the drug targets. Pancreatic tumours are driven by a mutated gene called KRAS, which is present in more than 90% of cases. KRAS produces a protein called RAS, which acts like a molecular switch stuck in the "on" position, telling cells to keep dividing. Daraxonrasib is a RAS inhibitor — it locks onto that protein and shuts it off. Scientists have spent decades trying to target RAS directly, and the protein was long considered "undruggable." Roughly 67,000 people in the US are diagnosed with pancreatic cancer each year, according to the American Cancer Society. (BBC News)
The approval is based on a late-stage clinical trial of 500 patients. Those who took daraxonrasib daily had an average survival time of 13.2 months, compared with 6.6 months for patients receiving chemotherapy. The most common side effects were rash, diarrhoea, nausea, fatigue, and vomiting. About 44% of patients on daraxonrasib experienced severe side effects, compared with 57.5% of those on chemotherapy in the same trial. (BBC News)
The broader context here is the comparative safety and efficacy picture. Daraxonrasib produced fewer severe side effects than chemotherapy while doubling average survival time. That does not mean the drug is risk-free — a 44% severe-side-effect rate is substantial and will influence how cancer specialists decide when to prescribe it relative to existing treatments. But the trial data give doctors a meaningful signal on both how well the drug works and how tolerable it is.
Former US Senator Ben Sasse, diagnosed with Stage 4 pancreatic cancer in December, is enrolled in a clinical trial for daraxonrasib and has said it helped shrink his tumours. His case has drawn public attention to the drug, though the FDA's decision rests on trial data from the full study population rather than individual reports.
The FDA's designation of the approval as first-in-class — meaning no prior targeted therapy of this specific type had reached this stage for metastatic pancreatic cancer — reflects the novelty of directly inhibiting the RAS protein. The agency also permitted expanded access to the drug in May 2026, before formal approval, which signalled regulatory urgency given the severity of the disease and the lack of effective treatments. (Cancer.org, FDA expanded-access notice)
Several questions remain outside the scope of the current approval. The trial compared daraxonrasib to chemotherapy alone, but the best strategy — using the drug alongside or instead of existing chemotherapy regimens — will depend on future studies. The survival figures reflect averages across a trial population; real-world outcomes in broader groups of patients with varying health conditions and prior treatments may differ.
For clinicians, the approval adds a targeted option in a disease where standard chemotherapy has offered limited benefit. For patients, the doubling of average survival is a concrete gain. The drug's long-term impact on the pancreatic cancer treatment landscape will depend on post-marketing experience, combination trials, and whether survival benefits hold in broader populations.
